Why R&D innovation holds the key to greater patient impact
European Pharmaceutical Review
MAY 2, 2023
Clinical trials Growing internal capabilities Approximately 90 percent of the investment required to develop new medicines is the cost of conducting clinical trials. Strengthening logistical capabilities One of the most unnecessary clinical trial burdens can be site inefficiencies, particularly where sites exist that do not recruit.
99 
Let's personalize your content